Covid, WHO: “The use of plasma to treat the infection is not recommended”

Treating Covid with hyperimmune plasma, or with a blood transfusion containing antibodies from other recovered patients, at first seemed more than promising. Thus began a series of trials all over the world, including in Italy, which recorded minimal benefits only in the first hours after the onset of the disease. But otherwise, the results weren’t as expected: the plasma did not reduce the risk of respiratory worsening or death.